Uric acid as a cardiovascular risk factor in arterial hypertension

Journal of Hypertension

Volumn 17, Issue 7, 1999, Pages 869-872

  Puig, Juan García ^a,c   Ruilope, Luis Miguel ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c C Costa Brava   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; ADENOSINE TRIPHOSPHATE; REACTIVE OXYGEN METABOLITE; URIC ACID;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; DEGRADATION; DISEASE ASSOCIATION; EDITORIAL; HUMAN; HYPERINSULINISM; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOXEMIA; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; SYNTHESIS; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; UROLITHIASIS;

EID: 0033053967     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917070-00001     Document Type: Editorial

References (30)

1. 1 Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34:1421-1431.
2. 2 Fessel WJ. High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 1980; 68:401-404.
3. 3 Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987; 82:421-426.
4. 4 Brand FN, McGee DL, Kannel WB, Stokes J, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 1985; 121:11-18.
5. 5 Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42:257-267.
6. 6 Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352:670-671.
7. 7 Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817-821.
8. 8 Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL. Blood pressure and renal function: therapeutic implications. J Hypertens 1996; 14:1259-1263.
9. 9 Mattei P, Arzilli F, Giovannetti R, Ponno G, Arrighi P, Taddei S, et al. Microalbuminuria and renal haemodynamics in essential hypertension. Eur J Clin Invest 1997; 27:755-760.
10. 10 Puig JG, Miranda ME, Mateos FA, Picazo ML, Jiménez ML, Calvin TS, et al. Hereditary nephropathy associated with hyperuricemia and gout. Arch Intern Med 1993; 153:357-365.
11. 11 Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemic related to decreased urate secretion. Nephron 1991; 59:364-368.
12. 12 Roch-Ramel F, Diezi J. Renal transport of organic ions and uric acid. In: Schrier RW, Gottschalk CW (editors): Diseases of the kidney, 6th edn, Vol. 1. Boston: Little Brown & Co.; 1996, pp. 231-249.
13. 13 Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998; 32:917-933.
14. 14 Capuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 1993; 270:354-359.
15. 15 Puig JG, Michán AD, Jiménez ML, Pérez de Ayala C, Mateos FA, Capitán CF et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 1991; 151:726-732.
16. 16 Sánchez M, Coca A. Insulinorresistencia, metabolismo celular del calcio e hipertensión arterial esencial. Papel del músculo esquelético. Med Clin (Barc) 1996; 107:102-106.
17. 17 Rocchini AP. The relationship of sodium sensitivity to insulin resistance. Am J Med Sci 1994; 307(suppl 1):S75-S80.
18. 18 Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997; 30:928-931.
19. 19 DeFronzo R. The effect of insulin on renal sodium metabolism: a review with clinical implications. Diabetologia 1981; 21:165-171.
20. 20 Strazzullo P, Cappuccio FP, Trevisan M, Siani A, Barba G, Ragone E, et al. The relationship of erythrocyte sodium-lithium countertransport to blood pressure and metabolic abnormalities in a sample of untreated middle-aged male workers. J Hypertens 1993; 11:815-822.
21. 21 McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312:159-163.
22. 22 Puig JG, Mateos FA. Inhibition of xanthine oxidase by allopurinol: a therapeutic option for ischemia induced pathological processes? Ann Rheum Dis 1989; 48:883-888.
23. 23 Fox IH. ATP degradation in specific diseases. J Lab Clin Med 1985; 106:101-110.
24. 24 Wooliscroft JO, Colfer H, Fox IH. Hyperuricemia in acute ilness: a poor prognostic sign. Am J Med 1982; 72:58-62.
25. 25 Rashid MA, William-Olsson G. Influences of allopurinol on cardiac complications in open heart operations. Ann Thorac Surg 1991; 52:127-130.
26. 26 Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 1991; 121:20-24.
27. 27 Olthoff KM, Millis JM, Imagawa DK, Nuesse BJ, Berus LI, Rosenthal JT, et al. Comparison of UW solution and Euro-Collins solutions for cold preservation of human liver grafts. Transplantation 1990; 49:284-290.
28. 28 Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci USA 1998; 95:4754-4759.
29. 29 Lacy F, O'Connor DT, Schmid-Schoenbein GW. Elevations in plasma hydrogen peroxide in hypertensive and normotensive subjects at genetic risk for hypertension. J Hypertens 1998; 16:291-303.
30. 30 Day RO, Birkett DJ, Hicks M, Miners JO, Graham GC, Brooks PM. New uses for allopurinol. Drugs 1994; 48:339-344.